What are the definitions and differences among arterial thrombosis, venous thrombosis, deep vein thrombosis (DVT), superficial thrombophlebitis, pulmonary embolism (PE), mural thrombus, thromboembolism, and venous thromboembolism (VTE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vasculopathology Terminology: Definitions and Key Distinctions

Venous thromboembolism (VTE) is the umbrella term encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), representing a single disease entity rather than separate conditions 1. Understanding the precise terminology is critical for appropriate risk stratification, treatment decisions, and prognostic assessment.

Core Definitions

Venous Thromboembolism (VTE)

VTE represents the formation of blood clots within the venous system, with an annual incidence of approximately 1-2 per 1,000 persons 2, 3. VTE broadly includes DVT, PE, superficial vein thrombosis (SVT), and thrombosis in other vascular territories (portal vein, mesenteric vein, inferior vena cava, superior vena cava, pelvis) 1.

Deep Vein Thrombosis (DVT)

DVT refers to thrombus formation in the deep venous system, most commonly affecting:

  • Lower extremity veins (70-90% of cases): femoral, iliac, popliteal veins, and IVC 4
  • Calf veins (distal DVT): carries 46% risk of PE progression 4
  • Upper extremity veins (5-20% of cases): increasingly common due to central venous catheters, with up to 40% associated PE risk 4
  • Pelvic veins: increasingly recognized source, particularly from peri-prostatic and peri-uterine plexuses 4

DVT management is stratified into 5 distinct categories based on anatomic location: upper extremity/SVC, lower extremity (IVC/pelvis/iliac/femoral/popliteal), distal lower extremity (calf), splanchnic vasculature, and catheter-related DVT 1.

Pulmonary Embolism (PE)

PE occurs when thrombi dislodge from venous clots and travel through the heart to pulmonary arteries 5. Approximately one-third of VTE manifests as PE, while two-thirds present as DVT alone 2. The correlation between thrombosis location and PE severity is well-established: PE incidence increases from 46% with calf-confined DVT to 67% with thigh involvement and 77% with pelvic vein involvement 4.

Superficial Thrombophlebitis (Superficial Vein Thrombosis)

SVT involves inflammation and thrombosis of superficial veins, most commonly the great saphenous vein (60-80% of cases) 6. Critically, SVT diagnosis confers a 5-fold increased risk of developing DVT or PE within 5 years, with highest risk in the first 3 months 6. This is not a benign condition and requires appropriate risk assessment.

Thromboembolism vs. Venous Thromboembolism

  • Thromboembolism: Generic term for any thrombus that dislodges and travels through the circulation
  • Venous thromboembolism (VTE): Specifically refers to thromboembolic events originating in the venous system 4

Mural Thrombus

A mural thrombus is a blood clot attached to the wall of a blood vessel or cardiac chamber. While this term can apply to either arterial or venous systems, it most commonly refers to cardiac thrombi (e.g., left ventricular mural thrombus post-myocardial infarction). In approximately 10-20% of PE cases, emboli arise from cardiac sources, though this represents a minor role in overall PE incidence 4.

Arterial vs. Venous Thrombosis: Critical Distinctions

Arterial and venous thrombosis are fundamentally different pathophysiologic entities 2:

Arterial Thrombosis

  • Primary mechanism: Atherosclerosis with platelet aggregation and minimal fibrin deposition 7
  • Clinical manifestations: Stroke, coronary heart disease, acute coronary syndrome
  • Pathophysiology: Vessel wall damage from atherosclerotic plaque rupture

Venous Thrombosis

  • Primary mechanism: Venous stasis, hypercoagulability, and vessel wall damage (Virchow's triad) 1
  • Clinical manifestations: DVT, PE, visceral vein thrombosis
  • Pathophysiology: Fibrin and platelet aggregation in low-flow states 7

Important caveat: While traditionally viewed as distinct entities, emerging evidence suggests shared risk factors (aging, immobility, obesity) and potential bidirectional relationships 2, 8. Patients with unprovoked VTE demonstrate higher rates of subclinical atherosclerosis 8.

Clinical Implications for Risk Stratification

The anatomic location of thrombosis directly impacts mortality and morbidity:

  • Proximal DVT (thigh/pelvic): Higher PE risk and severity; most severe PEs originate from proximal veins, though many begin in calf and propagate proximally before embolization 4
  • Distal DVT (calf): Lower but significant PE risk (46%) 4
  • Upper extremity DVT: 40% associated PE risk, often catheter-related 4
  • PE with hemodynamic compromise: Requires thrombolytic therapy (strong recommendation) 3

VTE increases mortality risk in cancer patients by 2-6 fold, with PE representing the most common cause of death at 30-day follow-up post-surgery 1.

Common Pitfalls to Avoid

  1. Do not dismiss superficial thrombophlebitis as benign: It carries substantial VTE risk requiring evaluation 6
  2. Do not assume all DVT originates in lower extremities: Upper extremity and visceral sources are increasingly recognized 4
  3. Do not treat arterial and venous thrombosis identically: They require different therapeutic approaches despite some overlapping risk factors 2, 7
  4. Do not underestimate calf DVT: Nearly half progress to PE 4

References

1
Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

5
Research

Overview of venous thromboembolism.

The American journal of managed care, 2017

6
Research

Superficial Vein Thrombosis.

The Medical clinics of North America, 2025

Related Questions

How does the pain of superficial thrombophlebitis differ from the pain of deep vein thrombosis (DVT)?
Can a transesophageal echocardiogram (TEE) detect a thrombus?
What are the most affordable medication options for treating deep vein thrombosis (DVT) and pulmonary embolism (PE)?
A 66-year-old man with a recent deep‑vein thrombosis treated with oral anticoagulation now presents three weeks later with dyspnea, confusion and hyponatremia (serum sodium 127 mmol/L). What is the most likely cause of his symptoms?
In an 86‑year‑old woman with severe dementia, left lower extremity edema without deep‑vein thrombosis, and a psoriatic rash being treated with topical betamethasone, is it appropriate to repeat a short course of oral prednisone for a flare?
In a patient with type 2 diabetes and a random urine creatinine of 645 mg/dL, what is the appropriate next step to assess renal involvement?
Can my patient return to work two hours after applying metronidazole (Metro) gel for bacterial vaginosis?
In heart failure patients with iron deficiency (ferritin < 100 µg/L or ferritin 100‑300 µg/L with transferrin saturation < 20 %), what is the role of ferric carboxymaltose, including its indications, recommended dosing regimen, monitoring parameters, and alternative therapies?
What is the most appropriate oral antibiotic for a female patient with a urinary tract infection who has already received ciprofloxacin, assuming normal renal function and no contraindications?
What are the differences between non‑compliant and semi‑compliant coronary balloons, including their expansion characteristics and clinical indications?
Can duloxetine (Cymbalta) and trazodone together cause serotonin syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.